title: Outcomes evaluation of a weekly nurse practitioner-managed symptom management clinic for patients with head and neck cancer treated with chemoradiotherapy.
abstract: OBJECTIVE
  To determine whether improved monitoring through close follow-up with a nurse practitioner (NP) could enhance treatment compliance and decrease frequency of hospitalizations.
  
  
  METHODS
  Retrospective chart review.
  
  
  METHODS
  An academic National Cancer Institute-designated comprehensive cancer center.
  
  
  METHODS
  151 patients aged 45-65 years diagnosed with stage III or IV oropharyngeal cancer.
  
  
  METHODS
  Patients were nonrandomized to one of two groups: a prechemotherapy clinic group and a weekly NP-led clinic group. After examination of descriptive statistics, multiple linear and logistic regressions were used to compare groups across patient outcomes.
  
  
  METHODS
  Hospitalization, chemotherapy dose deviations, and chemotherapy treatment completion.
  
  
  RESULTS
  The average number of visits during traditional treatment was three and, after initiation of the NP-led clinic, the number was six. The hospitalization rate was 28% in the traditional clinic group compared to 12% in the NP-led group. The rate of chemotherapy dose deviations was 48% in the traditional clinic group compared to 6% in the NP-led clinic group. Forty-six percent of patients in the traditional clinic group received the full seven scheduled doses of chemotherapy compared to 90% of patients seen in the NP-led clinic group.
  
  
  CONCLUSIONS
  A weekly NP-led symptom management clinic reduces rates of hospitalization and chemotherapy dose deviations and increases chemotherapy completion in patients receiving intensive chemoradiotherapy for oropharyngeal cancer.
  
  
  CONCLUSIONS
  Patients receiving chemoradiotherapy benefit from close monitoring for toxicities by NPs to successfully complete their treatment and avoid hospitalization.
  
  
  CONCLUSIONS
  Early interventions to manage toxicities in patients with head and neck cancer can improve outcomes. NPs are in a key position to manage these toxicities and, when symptoms are controlled, costs are reduced.
authors.affiliation: University of Michigan Medical Center in Ann Arbor.
authors.forename: Heidi
authors.initials: H
authors.lastname: Mason
authors.forename: Mary Beth
authors.initials: MB
authors.lastname: DeRubeis
authors.forename: Jared C
authors.initials: JC
authors.lastname: Foster
authors.forename: Jeremy M G
authors.initials: JM
authors.lastname: Taylor
authors.forename: Francis P
authors.initials: FP
authors.lastname: Worden
mesh_terms: D000046:Academic Medical Centers / Q000458:organization & administration; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002100:Cachexia / Q000209:etiology / Q000451:nursing; D002173:Cancer Care Facilities / Q000458:organization & administration; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000451:nursing*; D003681:Dehydration / Q000209:etiology / Q000451:nursing; D005767:Gastrointestinal Diseases / Q000209:etiology / Q000451:nursing; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008875:Middle Aged; D052016:Mucositis / Q000209:etiology / Q000451:nursing; D009722:Nurse Practitioners; D010044:Outpatient Clinics, Hospital / Q000458:organization & administration; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D010146:Pain / Q000209:etiology / Q000451:nursing; D010349:Patient Compliance; D015397:Program Evaluation; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel